Thank you for downloading the GMP IL-2 IL-7-IL-15-Cell-Therapy-Manufacturing-brochure

IL-2, IL-7, and IL-15 are critical cytokine components to many successful T and NK cell therapy programs.  Choosing these cytokines from a partner that can offer seamless translation from RUO to GMP means that the consistency across lots, the confidence in bioactivity, and cost-effectiveness are no longer barriers to manufacturing with consistency, translating with speed and scaling without limitation.  Learn more about these powerhouse cytokines in this brochure.

Latest Insights

Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors

Multiply Labs and Wilson Wolf are partnering to automate G-Rex® bioreactors for cheaper, more accessible cell therapy manufacturing. This partnership focuses on automating Wilson Wolf's innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.

Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy

Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.

Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success

Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.

Are you ready to scale?

Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.